Patent Blocks Zydus After Landmark US Approval For Dapagliflozin
AstraZeneca’s Farxiga Brand Set To Stand Until October 2025
With more than a dozen ANDA sponsors chasing AstraZeneca’s Farxiga SGLT2 inhibitor, Zydus Cadila has scooped the first FDA approval for a generic version of the game-changing type 2 diabetes drug. However, a key US patent stands in its way.
You may also be interested in...
Boehringer To Profit From Jardiance Well Into Second Half Of Decade
The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.
Boehringer’s Cyltezo, The Only Interchangeable Humira Biosimilar, Gets A New Form
Boehringer Ingelheim has welcomed a new FDA approval for its Cyltezo (adalimumab-adbm) interchangeable biosimilar, ahead of planned launch on 1 July.